AzurRx BioPharma, Inc. (AZRX): Price and Financial Metrics
AZRX Price/Volume Stats
| Current price | $3.45 | 52-week high | $26.30 |
| Prev. close | $3.38 | 52-week low | $3.36 |
| Day low | $3.38 | Volume | 629,000 |
| Day high | $3.66 | Avg. volume | 628,703 |
| 50-day MA | $5.85 | Dividend yield | N/A |
| 200-day MA | $9.42 | Market Cap | 32.17M |
AZRX Stock Price Chart Interactive Chart >
AzurRx BioPharma, Inc. (AZRX) Company Bio
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. The company's therapeutic products are administered to patients as oral non-systemic biologics. Its lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency for cystic fibrosis and chronic pancreatitis patients. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.
Latest AZRX News From Around the Web
Below are the latest news stories about AzurRx BioPharma Inc that investors may wish to consider to help them evaluate AZRX as an investment opportunity.
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO DepartsHere''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (NASDAQ: XLRN ) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Corvus Pharmaceuticals, Inc. NASDAQ: CRVS) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) IVERIC bio, Inc. (NASDAQ: ISEE ) Leap Therapeutics, Inc. (NASDAQ: LPTX ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 20) Ambrx Biopharma Inc. (NYSE: AMAM ) Absci Corporation (NASDAQ: ABSI ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aytu Biopharma, Inc. (NASDAQ: AYTU ) AzurRx BioPharma, Inc. (NA... |
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma TodayCompany to begin trading on Nasdaq under new ticker symbol, FBWI, effective September 22 Company to begin trading on Nasdaq under new ticker symbol, FBWI, effective September 22 |
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder StudyHere''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACH... |
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharmaBOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, regarding its recently announced merger with First Wave Bio, Inc. and adoption of the First Wave BioPharma name. The full text of the letter, which has also been posted to the Company''s website, is as follows: |
36 Stocks Moving In Tuesday's Mid-Day SessionGainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares climbed 25.5% to $6.00. The company on Monday announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractor chronic cough. HC Wainwright on Tuesday raised its price target on the stock. BTCS Inc. (NASDAQ: BTCS) shares climbed 23% to $10.25 as the company commenced trading on The Nasdaq Capital Market. Comm |
AZRX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -59.11% |
| 5-year | -86.73% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | -6.73% |
| 2019 | -14.05% |
Loading social stream, please wait...